EE514 A Cost-Effectiveness Analysis of Mosunetuzumab for Treatment of Third- or Higher-Line Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US)

Mosunetuzumab (Mosun), a novel CD20xCD3 T-cell engaging bispecific antibody, has received accelerated approval by the US Food and Drug Administration for adult patients with R/R FL after at least 2 prior therapies (3L+). We sought to evaluate the cost-effectiveness of Mosun for the treatment of 3L+ R/R FL from a US-payer perspective.